Eribulin(CAS: 253128-41-5)

Eribulin is a marine-derived antitumor agent, used in the treatment of metastatic breast cancer and peripheral nerve sheath tumors. It is a synthetic analogue of dolastatin 10, with a chemical structure that includes a 12-membered macrolide ring and a thiazole moiety.

Eribulin is primarily used in the treatment of metastatic breast cancer and peripheral nerve sheath tumors. It is also under investigation for other types of cancers and has potential applications in combination therapy.

Eribulin is generally considered safe when used according to the approved dosing guidelines. However, it may cause side effects such as peripheral neuropathy, neutropenia, and fatigue. Patients should be monitored closely and take necessary precautions to manage these risks.

Eribulin should be stored at 2°C to 8°C (36°F to 46°F) in its frozen state. It should be kept away from heat, moisture, and direct light. The drug should be stored in the original container to maintain its stability and efficacy.